GSTZ1 and hepatocellular carcinoma: The results showed that Gstz1-KO promoted HCC progression, whereas 2-ME2 treatment significantly decreased the proliferation of parental and Gstz1-KO cells in vivo based on tumor number and liver-to-body weight ratio (Figure 4, B–D).